Pioneering centers in the derivation of the first human embryonic stem (ES) cells in France, with the authorization of the Agence de la Biomedicine, since 2005.
Leaders in the field of induced pluripotent stem cells (iPS) cell reprogramming, since 2007.
Complementary expertise including cell engineering, genome editing, transgenesis, large-scale and automated cell factory and molecular high-throughput screening for preclinical, clinical and industrial applications.